Abstract:BACKGROUND & OBJECTIVE:Several researches have reported that epidermal growth factor receptor (EGFR) is expressed frequently in hepatocellular carcinoma (HCC) and paratumor tissues, most likely to contribute to the biological characteristics of HCC, including invasion, metastasis, and resistance to chemotherapy and radiotherapy. The single agent of cetuximab and erlotinib can inhibit the proliferation of HCC cells in vivo and in vitro. This study was to investigate the effects of cetuximab combined erlotinib on the proliferation of HCC cells, and explore the molecular mechanism.METHODS:Increasing concentrations of cetuximab (5-500 mg/mL) and erlotinib (2.5-250 micromol/L) alone or in combination were administrated to HCC cell lines HepG2 and Bel-7402. The inhibitory effects of the drugs on cell proliferation at different time points were observed; the combination index (CI) of these two agents was calculated. The expression of key enzymes in EGFR signaling transduction pathway in HepG2 and Bel-7402 cells after different treatments was detected by Western blot.RESULTS:The single agent of cetuximab and erlotinib inhibited the proliferation of HCC cells in a time-and dose-dependent manner; after 72-hour treatment, the proliferation inhibition rates of HepG2 cells were (43.1+/-1.9)% and (83.4+/-1.3)%, and those of Bel-7402 cells were (35.1+/-2.6)% and (73.9+/-1.2)%. With maximal inhibitory effects of cetuximab combined erlotinib, the proliferation inhibition rates of HepG2 and Bel-7402 cells were (91.1+/-1.0)% and (84.6+/-1.1)%, respectively. The CIs of different concentrations of these two agents at different time points were all less than 1, suggested that they have obvious synergistic activity. The expression of activated key enzymes (p-EGFR, p-ERK1/2, p-AKT) in EGFR signaling transduction pathway in HepG2 and Bel-7402 cells were down-regulated more obviously when these two agents were administrated in combination.CONCLUSIONS:The single agent of cetuximab and erlotinib can inhibit the proliferation of HepG2 and Bel-7402 cells through down-regulating activated key enzymes in EGFR signaling transduction pathway, and they have obvious synergistic activity. The combined EGFR-targeting therapy on HCC xenografts in vivo and on HCC patients is worth of further exploration.

Synergistic Effect of MiR-146a Mimic and Cetuximab on Hepatocellular Carcinoma Cells

Synergistic Effect Of Mir-146a Mimic And Cetuximab On Hepatocellular Carcinoma Cells (Vol 2014, 384121, 2014)

MicroRNA-449a Suppresses Hepatocellular Carcinoma Cell Growth Via G1 Phase Arrest and the HGF/MET C-Met Pathway

Effect of Microrna-150 Up-Regulation on Proliferation and Apoptosis of Hepatocellular Carcinoma Cell Line SMMC-7721

[Effects of Cetuximab Combined Erlotinib on Proliferation of Human Hepatocellular Carcinoma Cell Lines HepG2 and Bel-7402].

Combination of Cetuximab and Rapamycin Enhances the Therapeutic Efficacy in Hepatocellular Carcinoma.

Biological functional role of miR-146 a-5 p on cell growth and caspase-3 / 7 activity via targeting TRAF 6 in hepatocellular carcinoma

MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma

Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma.

MicroRNA-30a Suppresses Tumor Progression by Blocking Ras/Raf/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma.

miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8

Downregulation of Mir-155-5p Enhances the Anti-Tumor Effect of Cetuximab on Triple-Negative Breast Cancer Cells Via Inducing Cell Apoptosis and Pyroptosis

MicroRNA-20a Suppresses Tumor Proliferation and Metastasis in Hepatocellular Carcinoma by Directly Targeting EZH1

MicroRNA-34a-5p enhances sensitivity to chemotherapy by targeting AXL in hepatocellular carcinoma MHCC-97L cells

microRNA-375 inhibits the malignant behaviors of hepatic carcinoma cells by targeting NCAPG2

Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness

Effects of Microrna-126 on Cell Proliferation, Apoptosis and Tumor Angiogenesis Via the Down-Regulating ERK Signaling Pathway by Targeting EGFL7 in Hepatocellular Carcinoma.

Mir-548c-5p Inhibits Proliferation and Migration and Promotes Apoptosis in Cd90(+) Hepg2 Cells

MiR-146a Enhances Angiogenic Activity of Endothelial Cells in Hepatocellular Carcinoma by Promoting PDGFRA Expression.

Effects of Mirna-140 on the Growth and Clinical Prognosis of SMMC-7721 Hepatocellular Carcinoma Cell Line

Mir-187-3p Inhibits the Metastasis and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Targeting S100A4.